中文名稱:鹽酸萘哌地爾 | 英文名稱:Naftopidil DiHCl |
CAS:57149-08-3 | 品牌: 阿拉丁 |
產(chǎn)地: 上海 | 保存條件: -80℃儲存 |
純度規(guī)格: 10mM in DMSO | 產(chǎn)品類別: 藥靶配體 藥靶配體 |
分子式: C24H28N2O3·2HCl | 分子量: 465.41 |
運輸條件: 超低溫冰袋運輸 | 產(chǎn)品規(guī)格: 1ml |
貨號: N409056 | 是否進口: 否 |
中文名:鹽酸萘哌地爾
英文名:Naftopidil DiHCl
英文別名:KT-611;1-(4-(2-methoxyphenyl)piperazin-1-yl)-3-(naphthalen-1-yloxy)propan-2-ol dihydrochloride
純度:10mM in DMSO
貨號:N409056
包裝:1ml
Cas號:57149-08-3
存儲溫度:-80℃儲存
產(chǎn)品介紹:
Information
Naftopidil DiHCl (KT-611) is a selective5-HT1Aandα1-adrenergic receptorantagonist withIC50of 0.1 μM and 0.2 μM, respectively.
In?vitro
Naftopidil diHCl possesses 5-HT1A agonistic properties in addition to being an α1-adrenoceptor antagonist. Naftopidil has growth inhibitory effect in androgen-sensitive and -insensitive human prostate cancer cell lines. Naftopidil inhibits the growth of androgen-sensitive LNCaP cells and androgen-insensitive PC-3 cells with IC50 of 22.2 μM and 33.2 μM, respectively. Cell growth inhibition by Naftopidil is due to the arrest of the G1 cell cycle. Expressions of p27kip1 and p21cip1 are significantly increased in LNCaP cells treated with Naftopidil. In PC-3 cells, Naftopidil induces p21cip1 but not p27kip1. Naftopidil produces a concentration-dependent inhibition of collagen-induced Ca2+ mobilization, maximum inhibition (22.9%) occurring with 40 μM Naftopidil. The adrenaline-induced rise in [Ca2+]i is inhibited dose dependently by Naftopidil. Naftopidil is significantly more effective than tamsulosin in relieving nocturia. Naftopidil induces G(1) cell-cycle arrest in both PCa cells and PrSC. In Naftopidil-treated PrSC, total interleukin-6 protein is significantly reduced with increased suppression of cell proliferation.
In?vivo
Oral administration of Naftopidil to nude mice inhibits the growth of PC-3 tumors as compared to vehicle-treated controls. Naftopidil improves bladder capacity and relaxed voiding via inhibition of afferent nerve activity. Naftopidil (0.1 μg–30 μg) transiently abolishes isovolumetric rhythmic bladder contraction. The amplitude of bladder contraction is decreased by intrathecal injection of naftopidil (3 μg–30 μg). Naftopidil selectively inhibits the phenylephrine-induced increase in prostatic pressure compared with mean blood pressure in the anesthetized dog model.
Cell?Data
cell?lines:BT474, HT1376, UMUC-3, T24, ACHN, DU-145, PC-3, LN-REC4, and LNCaP cells
Concentrations:20 μM, 40 μM
Incubation?Time:24 hours
Powder?Purity:≥99%
查看阿拉丁官網(wǎng)此產(chǎn)品相關(guān)對應頁面:https://www.aladdin-e.com/zh_cn/N409056.html
成立日期 | 2009-03-16 (17年) | 注冊資本 | 14130.676萬人民幣 |
員工人數(shù) | 500人以上 | 年營業(yè)額 | ¥ 1億以上 |
主營行業(yè) | 生物化工,化學試劑 | 經(jīng)營模式 | 工廠,試劑 |
產(chǎn)品名稱 | 價格 | 公司名稱 | 報價日期 | |
---|---|---|---|---|
詢價 |
VIP10年
|
上海升德醫(yī)藥科技有限公司
|
2025-04-13 | |
¥370.90 |
VIP13年
|
上海阿拉丁生化科技股份有限公司
|
2025-03-24 | |
詢價 |
VIP1年
|
陜西西化化學工業(yè)有限公司
|
2025-03-06 | |
¥136 |
VIP3年
|
TargetMol中國(陶術(shù)生物)
|
2025-02-28 | |
詢價 |
上海博湖生物科技有限公司
|
2022-09-02 | ||
¥999 |
深圳瑞愷德醫(yī)藥研發(fā)有限公司
|
2020-08-23 |